Skip to content

Resources

 

Hemophilia Treatment Centers

 

Many people with bleeding disorders use the resources of their hemophilia treatment center (HTC). Individuals who go to hemophilia treatment centers will not only find state-of-the art medical care, but also benefit from an experienced, caring staff that takes time to develop comprehensive treatment care plans for patients and families.

Local Hemophilia Treatment Centers:

 
  • Gulf States Hemophilia & Thrombophilia Center
    6655 Travis, Suite 100
    Houston, TX 77030
    Phone: 713-500-8360
  • Texas Children’s Hemophilia & Thrombosis Center
    6701 Fannin Street
    Suite 1580
    Houston, Texas 77030
    Phone: 832-822-4362
  • Children’s Blood and Cancer Center of Central Texas – Dell Children’s Specialty Pavillion
    4910 Mueller Blvd Ste 200
    Austin, TX 78723
    Phone: 512-628-1900
  • South Texas Hemophilia Treatment Center
    Gateway Medical Park
  • 8435 Wurzbach Road
    San Antonio, TX 78229
    Phone: 210-567-7000

Assistance Programs

Your Social Worker at your Hemophilia Treatment Center can help you navigate resources for financial assistance.

Please contact your Social Worker for a LSBDF Helping Hands referral application.

Hemophilia Assistance Program

Website-

Hemophilia Assistance Program

The Hemophilia Assistance Program helps Texans with hemophilia cover their medical bills. Assistance is provided with blood factor replacement products or reimbursement for health insurance premium payment.

Who is eligible for services?

HAP is available to anyone who

  • Lives in Texas
  • Is 18 or older
  • Has an income at or below 200 percent of federal poverty guidelines
  • Has a diagnosis of hemophilia from a licensed physician
  • Isn’t incarcerated or a ward of the state
  • Isn’t eligible for the Children with Special Health Care Needs Services Program, Medicaid or Medicare

PAN Foundation

https://www.panfoundation.org

News from HFA

  • Word from Washington: May 2023

    Lawmakers in May devoted close attention to the role that pharmacy benefits managers (PBMs) play in our health care system.  PBMs are middlemen that create and administer drug formularies on behalf of health insurers, self-insured employers, Medicaid, and other payers. PBMs choose which drugs a plan will cover, negotiate drug prices on behalf of payers, The post Word from Washington: May 2023 appeared first on Hemophilia Federation of America.

  • Pfizer Announces Positive Results from Hemophilia A and B Trial

    Pfizer Inc. today announced their Phase 3 BASIS clinical trial evaluating marstacimab has met its primary endpoints, having demonstrated statically significant and clinically meaningful effects. Marstacimab, a novel, investigational anti-tissue factor pathway inhibitor (anti-TFPI) being studied for the treatment of hemophilia A or B for people without inhibitors to Factor VIII (FVIII) or Factor IX The post Pfizer Announces Positive Results from Hemophilia A and B Trial appeared first on Hemophilia Federation of America.

  • FDA Finalizes Blood Donor Eligibility Guidance

    On May 11, 2023, the U.S. Food and Drug Administration released final guidance providing recommendations for evaluating blood and plasma donor eligibility using individual risk-based questions. Consistent with FDA’s January 2023 proposed guidance, the final guidance eliminates time-based donation deferrals and screening questions specific to men who have sex with men (MSM) and women who have The post FDA Finalizes Blood Donor Eligibility Guidance appeared first on Hemophilia Federation of America.

  • FDA issues response to Novo Nordisk’s request for concizumab approval

    Recently Novo Nordisk received a Complete Response Letter from the Food and Drug Administration for concizumab. Concizumab was submitted for regulatory approval in the U.S. for the treatment of hemophilia A and B with inhibitors in August 2022. In the letter, the FDA requested additional information related to the monitoring and dosing of patients to The post FDA issues response to Novo Nordisk’s request for concizumab approval appeared first on Hemophilia Federation of America.

  • The HELP Copays Act moves forward – now in the Senate as well as in the House 

    Protections for people who rely on copay assistance have been a top priority for HFA and many other patient groups for several years. That effort took a big step forward in April with the introduction of a first-ever Senate version (S. 1375) of the HELP Copays Act.   Sponsored by Sens. Kaine, Marshall, Markey, and Ernst, The post The HELP Copays Act moves forward – now in the Senate as well as in the House  appeared first on Hemophilia Federation of America.